You are here: Home: Audio Program Guide: CCU 3 | 2007: CCU 3 | 2007 Audio
 
  Go to interview with Alan P Venook, MD
Go to interview with Steven D Wexner, MD
Go to interview with Christopher Willett, MD
Go to interview with J Randolph Hecht, MD
  To listen to individual tracks, click the on the headphone.
To download tracks, right-click on the one you wish to download.
Venook, MD Alan P Venook, MD
Professor of Clinical Medicine
Associate Chief, Division of Medical Oncology
University of California, San Francisco
San Francisco, California



  
  Click here to download the entire interview  
Track 1 Incorporating curability and drug “holidays” in the paradigm of treating metastatic colorectal cancer
Track 2 Case discussion: Use of a chemotherapy holiday for a long-term responder
Track 3 Chemotherapy before surgery in potentially curative settings
Track 4 Current research and treatment issues in rectal cancer
Track 5 Clinical approach to adjuvant therapy for patients with rectal cancer
Track 6 Clinical trials incorporating EGFR inhibitors as first-line therapy
Track 7 Continuation of bevacizumab after disease progression
Track 8 Use of panitumumab for patients with advanced colorectal cancer
Track 9 Major ongoing adjuvant clinical trials in colon cancer
Track 10 Patient acceptance of rash as a side effect of adjuvant therapy
Track 11 EVEREST: Cetuximab dose escalation study for patients with metastatic colorectal cancer and no or slight skin reactions to cetuximab standard dose treatment
Track 12 Evolving data on capecitabine with oxaliplatin in the adjuvant and metastatic settings
     
Wexner, MD Steven D Wexner, MD
Chief, Division of Colorectal Surgery
Cleveland Clinic Florida
Weston, Florida

  
  Click here to download the entire interview  
Track 1 Initial evaluation of patients with rectal cancer
Track 2 Impact of neoadjuvant chemoradiation therapy on the ability to perform surgery
Track 3 Clinical use of neoadjuvant capecitabine
Track 4 Clinical use of transanal excision
Track 5 Laparoscopic surgery for patients with colon cancer
Track 6 Morbidity associated with laparoscopic surgery for colon cancer
Track 7 Benefit of open versus laparoscopic surgery
Track 8 Laparoscopic surgery for patients with rectal cancer
Track 9 Morbidity associated with laparoscopic surgery for rectal cancer
Track 10 Randomized trial comparing laparotomy to laparoscopic surgery for rectal cancer
Track 11 Sphincter preservation
Audio
Track 12 Bowel function and quality of life for patients with low rectal lesions
Audio
Track 13 Adequacy of lymph node sampling
Audio
Track 14 Synchronous primary lesion and hepatic metastases
Audio
Track 15 Management of hepatic metastases
Audio
Track 16 Referral of patients with Stage II colon cancer to a medical oncologist
Audio
Track 17 Virtual colonoscopy
Audio
     
Willett, MD Christopher Willett, MD
Chairman, Department of Radiation Oncology
Duke University Medical Center
Durham, North Carolina
  
  Click here to download the entire interview  
Track 1 Bevacizumab as a potential radiation sensitizer in rectal cancer
Track 2 Clinical trial of bevacizumab alone and concurrent with chemoradiation therapy in rectal cancer
Track 3 Direct evidence of antivascular effects of bevacizumab in rectal cancer
Track 4 Clinical response to neoadjuvant chemoradiation with bevacizumab in rectal cancer
Track 5 Capecitabine versus infusional 5-FU as neoadjuvant therapy in rectal cancer
Track 6 Pathologic complete response with neoadjuvant combined chemoradiation and targeted therapies
Track 7 Addition of oxaliplatin to neoadjuvant chemoradiation therapy for rectal cancer
Track 8 American College of Surgeons trial of local excision in patients with T2 rectal cancer

     
Hecht, MD J Randolph Hecht, MD
Clinical Professor of Medicine
Director, UCLA GI Oncology Program
Division of Hematology/Oncology
Department of Medicine
UCLA School of Medicine
Los Angeles, California		  
  Click here to download the entire interview  
Track 1 Recent developments in the treatment of metastatic colorectal cancer
Track 2 Emerging clinical data with panitumumab
Track 3 Recent clinical trials of first-line therapy in metastatic colorectal cancer
Track 4 XELOX-1/NO16966: CAPOX or FOLFOX4 with or without bevacizumab as first-line therapy
Track 5 Investigations of chemotherapy holidays in the treatment of metastatic disease
Track 6 Doublet antibodies in the treatment of metastatic colorectal cancer
Track 7 Side effects and tolerability of the anti-EGFR antibody panitumumab
arrow
Track 8 Current role of panitumumab in the treatment of metastatic colorectal cancer
arrow
Track 9 Predictors of response to anti-EGFR antibodies
arrow
Track 10 Clinical trial strategies incorporating biologic agents in the adjuvant setting
arrow
Track 11 Use of chemotherapy with biologic agents to render hepatic metastases resectable
arrow
Track 12 Safety of bevacizumab and its role in the adjuvant setting
arrow
Track 13 Identification of targets for biologic agents and the individualization of therapy